Ceftaroline-induced eosinophilic pneumonia

Pharmacotherapy. 2013 Jul;33(7):e166-9. doi: 10.1002/phar.1286. Epub 2013 May 3.

Abstract

We present a case of eosinophilic pneumonia due to ceftaroline used for the treatment of methicillin-resistant Staphylococcus aureus bacteremia associated with a postoperative spinal infection. Our patient developed shortness of breath and hypoxemia on the fifth week of ceftaroline therapy. Chest imaging disclosed diffuse bilateral infiltrates. Laboratory abnormalities included peripheral eosinophilia and eosinophilic predominant bronchoalveolar lavage fluid. The combination of ceftaroline discontinuation plus initiation of steroid treatment resulted in complete resolution of signs, symptoms, and radiologic abnormalities. We speculate about possible mechanisms underlying this adverse event and diagnostic criteria for drug-induced eosinophilic pneumonia.

Keywords: adverse event; ceftaroline; eosinophilic pneumonia.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / therapeutic use
  • Bronchoalveolar Lavage Fluid / chemistry
  • Ceftaroline
  • Cephalosporins / adverse effects*
  • Cephalosporins / therapeutic use
  • Glucocorticoids / therapeutic use
  • Humans
  • Male
  • Methicillin-Resistant Staphylococcus aureus / isolation & purification
  • Middle Aged
  • Pulmonary Eosinophilia / chemically induced*
  • Pulmonary Eosinophilia / drug therapy
  • Staphylococcal Infections / drug therapy

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Glucocorticoids